EP1667695A4 - Oligonucleotides targeting prion diseases - Google Patents

Oligonucleotides targeting prion diseases

Info

Publication number
EP1667695A4
EP1667695A4 EP04787566A EP04787566A EP1667695A4 EP 1667695 A4 EP1667695 A4 EP 1667695A4 EP 04787566 A EP04787566 A EP 04787566A EP 04787566 A EP04787566 A EP 04787566A EP 1667695 A4 EP1667695 A4 EP 1667695A4
Authority
EP
European Patent Office
Prior art keywords
prion diseases
oligonucleotides targeting
targeting prion
oligonucleotides
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04787566A
Other languages
German (de)
French (fr)
Other versions
EP1667695A2 (en
Inventor
Jean-Marc Juteau
Andrew Vaillant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/004573 external-priority patent/WO2004024919A1/en
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of EP1667695A2 publication Critical patent/EP1667695A2/en
Publication of EP1667695A4 publication Critical patent/EP1667695A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
EP04787566A 2003-09-11 2004-09-10 Oligonucleotides targeting prion diseases Withdrawn EP1667695A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2003/004573 WO2004024919A1 (en) 2002-09-13 2003-09-11 Non-sequence complementary antiviral oligonucleotides
US58462704P 2004-06-06 2004-06-06
PCT/IB2004/003740 WO2005025487A2 (en) 2003-09-11 2004-09-10 Oligonucleotides targeting prion diseases

Publications (2)

Publication Number Publication Date
EP1667695A2 EP1667695A2 (en) 2006-06-14
EP1667695A4 true EP1667695A4 (en) 2007-01-31

Family

ID=34315467

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04787566A Withdrawn EP1667695A4 (en) 2003-09-11 2004-09-10 Oligonucleotides targeting prion diseases

Country Status (4)

Country Link
EP (1) EP1667695A4 (en)
AU (1) AU2004271807A1 (en)
CA (1) CA2538245A1 (en)
WO (1) WO2005025487A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119643A1 (en) * 2005-05-12 2006-11-16 Replicor Inc. Anti-ocular angiogenesis molecules and their uses
WO2006122409A1 (en) * 2005-05-16 2006-11-23 Replicor Inc. Antimicrobial molecules and their uses
WO2006130949A1 (en) * 2005-06-08 2006-12-14 Replicor Inc. Anti amyloid-related disease molecules and their uses
CA2624686A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
AU2006302022A1 (en) * 2005-10-06 2007-04-19 University Of Delaware G-rich polynucleotides for the treatment of Huntington's Disease
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1333090A1 (en) * 2002-02-01 2003-08-06 NascaCell GmbH Prionprotein-specific aptamers
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862653B1 (en) * 1995-10-26 2002-01-16 Winnacker, Ernst-Ludwig, Prof. NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION
GB0012054D0 (en) * 2000-05-18 2000-07-12 Isis Innovation Ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1333090A1 (en) * 2002-02-01 2003-08-06 NascaCell GmbH Prionprotein-specific aptamers
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORDEIRO Y ET AL: "DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49400 - 49409, XP002196440, ISSN: 0021-9258 *
SETHI ET AL: "Postexposure prophylaxis against prion disease with a stimulator of innate immunity", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 360, no. 9328, 20 July 2002 (2002-07-20), pages 229 - 230, XP005061830, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
EP1667695A2 (en) 2006-06-14
WO2005025487A3 (en) 2005-12-01
WO2005025487A2 (en) 2005-03-24
AU2004271807A1 (en) 2005-03-24
CA2538245A1 (en) 2005-03-24
WO2005025487A9 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
GB0322880D0 (en) Purchasing scheme
GB0312309D0 (en) Targeted liposome
IL173280A0 (en) Otoscope
ZA200605863B (en) PEF-TU expression units
EP1614386A4 (en) Ultrasonograph
EP1665987A4 (en) Ultrasonograph
ZA200605862B (en) PGRO Expression Units
GB0327384D0 (en) Gene therapy
EP1667695A4 (en) Oligonucleotides targeting prion diseases
GB0308968D0 (en) Medicaments
GB0314733D0 (en) Medicaments
IL176603A0 (en) Targeted immunogens
GB2401043B (en) Drug
GB2398992B (en) Underwear
IL172407A0 (en) Dna-based aptamers for human cathepsin g
GB0316889D0 (en) Pharmaceutical agents
GB0302315D0 (en) Novel therapeutic target
GB0315993D0 (en) Peptide-based linker
EP1624073A4 (en) Drug
GB0100702D0 (en) Prion related diseases
GB0320952D0 (en) Targeted delivery
GB0409528D0 (en) Body armour
GB0325021D0 (en) Therapeutic combinations
GB0310243D0 (en) Target
GB0312982D0 (en) Pavement advertiser

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060329

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

R17D Deferred search report published (corrected)

Effective date: 20060622

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7088 20060101AFI20051208BHEP

17Q First examination report despatched

Effective date: 20070621

R17C First examination report despatched (corrected)

Effective date: 20070621

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091023